Compare LUNG & AIRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | AIRS |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.1M | 182.4M |
| IPO Year | 2020 | 2021 |
| Metric | LUNG | AIRS |
|---|---|---|
| Price | $1.87 | $1.42 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | $3.40 | ★ $4.50 |
| AVG Volume (30 Days) | 261.6K | ★ 838.4K |
| Earning Date | 10-27-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $90,497,000.00 | ★ $151,818,000.00 |
| Revenue This Year | $0.06 | N/A |
| Revenue Next Year | $8.58 | $2.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.13 | $1.41 |
| 52 Week High | $2.89 | $12.00 |
| Indicator | LUNG | AIRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 26.01 |
| Support Level | $1.20 | N/A |
| Resistance Level | $2.12 | $2.03 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 51.79 | 5.43 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
AirSculpt Technologies Inc is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Its proprietary and patented AirSculpt method is minimally invasive because it requires no needle, no scalpel, no stitches, and no general anesthesia. It offers fat removal procedures across treatment areas and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its segment is direct medical procedure services.